Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Global Granulysin (GNLY) Market Trends, Growth Forecast, and Competitive Analysis to 2035 | $1.51 Billion Opportunity Driven by Diagnostics, Cancer Research, and APAC Growth

GlobeNewswire

Dublin, Nov. 04, 2026 -- "Granulysin (GNLY) Market Report: Trends, Forecast and Competitive Analysis to 2035" has been added to ResearchAndMarkets.com's offering.

The global granulysin (GNLY) market is expected to reach an estimated $1.51 billion by 2035, expanding at a CAGR of 10.6% from 2026 to 2035. Growth is being driven by collaborations between biotechnology companies and research institutions, rising adoption of GNLY biomarkers in diagnostic assays, and increasing demand for granulysin in cancer treatment research.

The outlook for the global granulysin (GNLY) market remains promising, with opportunities across medical science and experimental research applications.

Key Highlights by Segment

  • Within the type category, 9 KDa GNLY is expected to record higher growth over the forecast period.
  • Within the application category, medical science is expected to experience higher growth.
  • APAC is expected to register the highest regional growth over the forecast period.

Emerging Trends in the Granulysin (GNLY) Market

Advances in immunology, biotechnology, and personalized medicine are expanding the potential use of GNLY in diagnostics and targeted therapies for infectious diseases, cancer, and inflammatory conditions.

  • Expanded research activity: Biotechnology companies and academic institutions are investigating GNLY as a diagnostic and prognostic biomarker and as a therapeutic target.
  • Improved biomarker detection: High-throughput screening, multiplex assays, and other advanced platforms are enabling faster and more accurate GNLY detection and quantification.
  • Personalized medicine: GNLY testing could support patient stratification and more targeted treatment strategies based on individual immune profiles.
  • Broader clinical applications: Increasing research into infectious, autoimmune, inflammatory, and oncologic diseases is widening the potential market for GNLY-based products.
  • Supportive regulatory and commercial conditions: Clearer pathways for immune biomarker products and rising healthcare investment in emerging markets could accelerate commercialization and adoption.

Recent Developments in the Granulysin (GNLY) Market

  • Research into GNLY's antimicrobial properties is supporting the development of potential treatments for infectious diseases, including those involving resistant pathogens.
  • GNLY is being evaluated in immunotherapy strategies designed to improve targeted immune responses against cancer cells.
  • Innovations in drug delivery and biomarker identification are improving the stability, targeting, and potential efficacy of GNLY-based therapies.
  • Clinical research addressing HIV, tuberculosis, viral infections, and cancer is broadening the potential diagnostic and therapeutic use of GNLY.
  • Strategic collaborations among biotechnology companies, research institutions, and healthcare organizations are helping advance product development, validation, and commercialization.

Strategic Growth Opportunities in the Granulysin (GNLY) Market

  • Diagnostic development: Companies can develop GNLY assays for disease detection, prognosis, immune monitoring, and treatment selection.
  • Targeted therapeutics: GNLY's activity against infected and malignant cells creates opportunities in antimicrobial treatments and cancer immunotherapy.
  • Advanced delivery technologies: Nanotechnology, gene editing, and targeted delivery systems could improve therapeutic precision while reducing adverse effects.
  • Research and commercial partnerships: Collaboration can provide access to specialized expertise, clinical validation, funding, and regulatory capabilities.
  • Emerging-market expansion: Improving healthcare infrastructure and the high burden of infectious diseases offer opportunities for affordable GNLY-based diagnostics and therapies.

Granulysin (GNLY) Market Drivers and Challenges

Market Drivers

  • Technological advances: Progress in recombinant DNA technology, monoclonal antibody development, diagnostic platforms, and biomarker analysis is supporting GNLY research and product development.
  • Rising disease prevalence: Increasing cases of cancer, autoimmune disorders, and infectious diseases are strengthening demand for new immune-based diagnostics and therapies.
  • Biopharmaceutical investment: Funding from governments, private investors, pharmaceutical companies, and academic institutions is accelerating research, clinical trials, and product pipelines.
  • Regulatory support: Approval pathways for biopharmaceuticals, biomarkers, and personalized medicine products can facilitate the clinical adoption of GNLY-based solutions.
  • Adoption of precision medicine: The growing use of patient-specific treatment strategies is increasing interest in GNLY as a biomarker and therapeutic target.

Market Challenges

  • Regulatory complexity: Extensive safety, efficacy, and clinical validation requirements can delay approvals and increase development expenses.
  • High development and manufacturing costs: Specialized research, clinical trials, and biotechnology production processes can limit participation and product accessibility.
  • Competitive and patent pressures: Competing immunotherapies, intellectual property disputes, and patent expirations could affect market exclusivity and profitability.

Granulysin (GNLY) Companies

Market participants compete through product quality, R&D investment, manufacturing expansion, infrastructure development, and integration across the value chain. These strategies are intended to strengthen innovation, improve cost efficiency, meet rising demand, and expand customer reach.

Companies profiled in the report include:

  • BioLegend
  • BD Biosciences
  • ThermoFisher Scientific
  • Proteintech Group
  • Merck KGaA

Country Wise Outlook for the Granulysin (GNLY) Market

  • United States: Clinical research is focusing on GNLY applications in cancer immunotherapy and infectious diseases. Strong biotechnology capabilities, research funding, and healthcare infrastructure support product development and potential adoption.
  • China: Government-backed biotechnology initiatives and investment by domestic companies are expanding GNLY research, particularly for tuberculosis and viral infections. A large patient population also supports clinical studies and commercialization opportunities.
  • Germany: Collaboration between academic and industry participants is advancing research into GNLY's immunomodulatory properties. The country's precision medicine focus, biotechnology sector, and access to European Union funding support continued development.
  • India: Research is concentrating on GNLY applications for regionally prevalent infectious diseases, including tuberculosis. Healthcare investment, demand for affordable therapies, and increasing awareness of immunotherapy are expected to support growth.
  • Japan: An advanced biotechnology ecosystem and established regulatory framework are supporting GNLY research in cancer immunotherapy and infectious disease management. International partnerships are also helping expand potential applications.

For more information about this report visit https://www.researchandmarkets.com/r/flj2d7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. Economic Confidence Slips Ahead of the Holidays, but Consumers Remain Determined to Celebrate, Circana FindsNew study reveals a growing gap between how consumers feel about the economy and how they plan to approach the holiday season.
  2. QBTS Shareholders Have Rights – If You Lost Money Investing in D-Wave Quantum Inc. Contact Robbins LLP for Information About Recovering Your LossesD-Wave Quantum Inc. faces allegations it overstated its business and financial prospects.
  3. Global Dental Crowns and Bridges Market Size, Share and Trends Forecast 2026-2033 | CAD/CAM and Zirconia Innovation Drive Growth to US$6.75 Billion at 8.1% CAGR"Dental Crowns and Bridges Market Size, Share & Trends Analysis Report by Product, End Use, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.
  4. AutomotiveHydrogen Internal Combustion Engine (H2ICE) Market to Reach $2.3 Billion by 2031, Driven by Government Mandates and Surging Hydrogen Infrastructure Investment“H2ICE is emerging as a practical lower-carbon mobility option as hydrogen infrastructure expands and pressure to cut transport emissions intensifies.”
  5. FinanceImportant Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); O-I Glass, Inc. (NYSE: OI); Planet Fitness, Inc. (NYSE: PLNT); and Sprout Social, Inc. (NASDAQ: SPT): Grabar Law Office is Investigating Claims on Your BehalfShareholder Notice: Erasca, Inc. (NASDAQ: ERAS); O-I Glass, Inc. (NYSE: OI); Planet Fitness, Inc. (NYSE: PLNT); and Sprout Social, Inc. (NASDAQ: SPT)
  6. HealthcareAustin Commercial Real Estate Firm Austin Tenant Advisors Celebrates Nathan K. Smith's 20 Years Representing TenantsAustin Tenant Advisors President Nathan K. Smith marks two decades and more than 450 commercial lease and purchase transactions, helping Austin businesses negotiate office, warehouse, retail, and medical office deals on equal footing with landlords.